首页> 外文期刊>Drug development and industrial pharmacy >Design and evaluation of D-α tocopheryl polyethylene glycol 1000 succinate emulsified poly-ε-caprolactone nanoparticles for protein/peptide drug delivery
【24h】

Design and evaluation of D-α tocopheryl polyethylene glycol 1000 succinate emulsified poly-ε-caprolactone nanoparticles for protein/peptide drug delivery

机译:设计和d-α生育酚聚乙二醇1000琥珀酸酯的评价乳化的蛋白质/肽的药物递送聚ε己内酯的纳米颗粒

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Incorporation of proteins/peptide drugs into nanoparticulate drug delivery system is one of the effective approaches to increase the stability of protein/peptide drugs against enzymatic degradation, to release them in a controlled fashion and to achieve site-specific drug delivery. Objective: Our goal was to design and evaluate poly-ε-caprolactone (PCL) nanoparticles using bovine serum albumin (BSA) as a model protein. d-α-tocopheryl polyethylene glycol 1000 (vitamin E TPGS) was used as an emulsifier in the fabrication of these nanoparticles. Methods: Double emulsion solvent evaporation method was employed to formulate BSA-loaded PCL nanoparticles and the nanoparticles thus prepared were further characterized. Results: The size of BSA-loaded PCL nanoparticles were in the range of 400-500 nm with a polydispersity index (PDI) of 0.195 and zeta potential was about -28.6 mV. Scanning electron microscopy (SEM) confirmed the presence of smooth and spherical surface of nanoparticles. Encapsulation efficiency was about 85% and a yield of 70-75% was attained. BSA was released in a biphasic pattern with an initial 20% release within 2 h followed by a slower release patter over 5 days. Flow cytometry and fluorescence microscopy was used to study the uptake of these nanoparticles. Circular dichroism (CD) results showed that there was no significant effect of formulation conditions on the secondary structure of BSA. Conclusion: Based on the results obtained, these TPGS-emulsified PCL nanoparticles proved to be potential carriers for the delivery of protein/peptide drugs.
机译:背景:将蛋白质/肽药物掺入纳米颗粒药物递送系统中是提高蛋白质/肽药物抵抗酶促降解的稳定性,以受控方式释放它们并实现位点特异性药物递送的有效方法之一。目的:我们的目标是使用牛血清白蛋白(BSA)作为模型蛋白来设计和评估聚ε-己内酯(PCL)纳米颗粒。 d-α-生育酚聚乙二醇1000(维生素E TPGS)在这些纳米颗粒的制备中用作乳化剂。方法:采用双乳化溶剂蒸发法制备负载BSA的PCL纳米粒子,并对其进行了表征。结果:负载BSA的PCL纳米颗粒的尺寸在400-500 nm范围内,多分散指数(PDI)为0.195,ζ电位约为-28.6 mV。扫描电子显微镜(SEM)证实了纳米颗粒的光滑球形表面的存在。包封效率为约85%,并且产率为70-75%。 BSA以两相模式释放,在2小时内初始释放20%,然后在5天内缓慢释放。流式细胞仪和荧光显微镜用于研究这些纳米颗粒的摄取。圆二色性(CD)结果表明,配制条件对BSA的二级结构没有显着影响。结论:基于获得的结果,这些TPGS乳化的PCL纳米颗粒被证明是蛋白质/肽药物递送的潜在载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号